Form 4: Stoke Therapeutics Executive Sells Shares to Cover Tax Obligations

A Stoke Therapeutics executive sold shares to cover tax liabilities related to vested stock units.

Summary

• Barry C. Ticho, Chief Medical Officer of Stoke Therapeutics, sold 13,945 shares of common stock on December 6, 2024.
• The sale was mandated by the issuer to satisfy tax withholding liabilities associated with the vesting of restricted stock units.
• The shares were sold at a weighted average price of $12.7775 per share.
• The transactions occurred at prices ranging from $11.93 to $13.46 per share.

Sentiment

Score: 5

Explanation: The document describes a routine transaction related to executive compensation and tax obligations, which is neither positive nor negative for the company's overall outlook.

Industry Context

Executive stock sales are a common occurrence, often related to compensation and tax obligations. This transaction is not unusual for a publicly traded company.

Comparison to Industry Standards

• Executive stock sales for tax purposes are a standard practice across the biotechnology industry.
• Many companies, such as Biogen and Vertex Pharmaceuticals, have similar filings related to executive stock transactions.
• The price range of the sale is within the typical fluctuations seen in the market for similar companies.

Stakeholder Impact

• The stock sale has a minimal impact on shareholders as it is a routine transaction for tax purposes.

Key Dates

Keywords

Stoke Therapeutics, stock sale, executive, tax liabilities, restricted stock units, STOK